Literature DB >> 27520521

The Fluoxetine and Suicide Controversy : A Review of the Evidence.

D Healy1.   

Abstract

Evidence is emerging that a range of psychotropic drugs may precipitate akathisia and/or panic reactions in predisposed patients. The use of fluoxetine has hitherto been the most notable example of this occurrence. These reactions may foster the genesis of suicidal ideation in a small proportion of patients. At present, it is not clear what biological mechanism may underlie this finding. The serotonin (5-hydroxytryptarnine; 5-HT) system may be involved in these reactions.The best management of such reactions will involve counselling patients beforehand about the possibility of these reactions, stopping treatment with the agents if such a reaction is suspected, or adding an agent with 5-HT1A antagonistic properties (e.g. propranolol) to the treatment regimen.

Entities:  

Year:  1994        PMID: 27520521     DOI: 10.2165/00023210-199401030-00007

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  53 in total

Review 1.  Modulatory role of serotonin in neural information processing: implications for human psychopathology.

Authors:  M R Spoont
Journal:  Psychol Bull       Date:  1992-09       Impact factor: 17.737

Review 2.  Antidepressants and suicide risk: issues of chemical and behavioral toxicity.

Authors:  A Molcho; M Stanley
Journal:  J Clin Psychopharmacol       Date:  1992-04       Impact factor: 3.153

3.  Biological suicide research: outcome and limitations.

Authors:  H M van Praag
Journal:  Biol Psychiatry       Date:  1986-11       Impact factor: 13.382

4.  Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness.

Authors:  R M Post; J Kotin; F K Goodwin; E K Gordon
Journal:  Am J Psychiatry       Date:  1973-01       Impact factor: 18.112

5.  Suicidality and fluoxetine: is there a relationship?

Authors:  M Fava; J F Rosenbaum
Journal:  J Clin Psychiatry       Date:  1991-03       Impact factor: 4.384

6.  Monoamine metabolites in CSF and suicidal behavior.

Authors:  L Träskman; M Asberg; L Bertilsson; L Sjöstrand
Journal:  Arch Gen Psychiatry       Date:  1981-06

7.  Paradoxical worsening of depressive symptomatology caused by antidepressants.

Authors:  N F Damluji; J M Ferguson
Journal:  J Clin Psychopharmacol       Date:  1988-10       Impact factor: 3.153

Review 8.  Does treatment with antidepressant medication increase suicidal behavior?

Authors:  M J Goldblatt; A F Schatzberg
Journal:  Int Clin Psychopharmacol       Date:  1991       Impact factor: 1.659

9.  Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.

Authors:  J W Maas; S H Koslow; M M Katz; C L Bowden; R L Gibbons; P E Stokes; E Robins; J M Davis
Journal:  Am J Psychiatry       Date:  1984-10       Impact factor: 18.112

10.  CSF monoamine metabolites of depressed patients during illness and after recovery.

Authors:  L Träskman-Bendz; M Asberg; L Bertilsson; P Thorén
Journal:  Acta Psychiatr Scand       Date:  1984-04       Impact factor: 6.392

View more
  3 in total

1.  In the grip of the python: conflicts at the university-industry interface.

Authors:  David Healy
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

Review 2.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness.

Authors:  M G Harris; P Benfield
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.